GB2371303A - Receptor polypeptides with immunomodulatory activity - Google Patents

Abstract

An isolated G-protein coupled receptor polypeptide having immunomodulatory activity comprising: <SL> <LI>(i) the amino acid sequence of SEQ ID NO:2 or <LI>(ii) a variant thereof which is capable of immunmodulatory activity or <LI>(iii) a fragment of (i) or (ii) which is capable of immunomodulatory activity. </SL> The polypeptide is referred to as HIPHUM 0000070 and may be used to identify agents that may be used in the treatment of diseases of immune, autoimmune, immunodeficiency or inflammatory origin.

Description

PROTEIN

Field of the Invention The present invention relates to receptor polypeptides having immunomodulatory activity.

Background of the Invention G-protein coupled receptors (GPCRs) are a super-family of membrane receptors that mediate a wide variety of biological functions. Upon binding of extracellular ligands, GPCRs interact with a specific subset of heterotrimeric G proteins that can, in their activated forms, inhibit or activate various effector enzymes and/or ion channels. All GPCRs are predicted to share a common molecular architecture consisting of seven transmembrane helices linked by alternating intracellular and extracellular loops. The extracellular receptor surface has been shown to be involved in ligand binding whereas the intracellular portions are involved in G protein recognition and activation.

Summary of the Invention A novel receptor polypeptides having immunomodulatory activity, referred to herein as HIPHUM 0000070, is now provided. HIPHUM 0000070 is shown to be primarily expressed in a wide variety of tissues tested (figure 1). The receptor was expressed in all immune cells tested including T cells, B cells, monocytes and dendriditc cells (figure 2). Hiphum 70 was upregulated in Hepatitis B-infected cells and in lung from asthma and COPD patients (Figure 2). Hiphum 70 was expressed in endothelial cells, RA synovium and osteoblasts (Figures 2 and 3). Receptor expression was upregulated in frontal cortex from Alzheimer's, Huntington's chorea and myotonic dystrophy patients (Figure 3). Hiphum 70 was down-regulated in cartilage from osteoarthritic knee (Figure 3). The novel receptor polypeptides having immunomodulatory activity is a screening target for the identification and development of novel pharmaceutical agents, including modulators of receptor polypeptides having immunomodulatory activity. These agents may be used in the treatment and/or prophylaxis of disorders such as diseases of immune, autoimmune,

immunodeficiency or inflammatory origin such as : asthma, COPD, bronchitis, rhinitis, allergy, rheumatoid arthritis, dermatitis, general inflammation (e. g. tendonitis, bursitis, etc. ), inflammatory pain, Crohn's disease, ulcerative colitis, inflammatory bowel syndrome, gastritis, colitis, Alzhiemer's disease, AIDS, severe combined immunodeficiency, viral infections, bacterial infections, acne vulgaris, septic shock, anaphylaxis, antibody mediated rejection, Type I diabetes mellitus, Goodpasture's syndrome, myasthenia gravis, systemic lupus erythematosis, Grave's disease, and systemic sclerosis, familial cold urticaria and Muckle-Wells syndrome.

Accordingly, the present invention provides an isolated receptor polypeptide having immunomodulatory activity comprising (i) the amino acid sequence of SEQ ID NO: 2; (ii) a variant thereof which is capable of immunomodulatory activity; or (iii) a fragment of (i) or (ii) which is capable of immunomodulatory activity.

According to another aspect of the invention there is provided a polynucleotide encoding a polypeptide of the invention which polynucleotide includes a sequence comprising: (a) the nucleic acid sequence of SEQ ID NO: 1 and/or a sequence complementary thereto; (b) a sequence which hybridises under stringent conditions to a sequence as defined in (a); (c) a sequence that is degenerate as a result of the genetic code to a sequence as defined in (a) or (b); or (d) a sequence having at least 60% identity to a sequence as defined in (a), (b) or (c).

The invention also provides: an expression vector which comprises a polynucleotide of the invention and which is capable of expressing a polypeptide of the invention; a host cell comprising an expression vector of the invention; a method of producing a polypeptide of the invention which method comprises maintaining a host cell of the invention under conditions suitable for obtaining expression of the polypeptide and isolating the said polypeptide;

an antibody specific for a polypeptide of the invention ; a method for identification of a substance that modulates receptor polypeptides having immunomodulatory activity and/or expression, which method comprises contacting a polypeptide, polynucleotide, expression vector or host cell of the invention with a test substance and determining the effect of the test substance on the activity and/or expression of the said polypeptide or the polypeptide encoded by the said polynucleotide, thereby to determine whether the test substance modulates receptor polypeptides having immunomodulatory activity and/or expression; a compound which modulates receptor polypeptide having immunomodulatory activity and which is identifiable by the method referred to above; a method of treating a subject having a disorder that is responsive to receptor polypeptides having immunomodulatory activity stimulation or modulation, which method comprises administering to said subject an effective amount of substance of the invention ; and use of a substance that stimulates or modulates receptor polypeptides having immunomodulatory activity in the manufacture of a medicament for the treatment or prophylaxis of a disorder that is responsive to stimulation or modulation of receptor polypeptide having immunomodulatory activity.

Preferably the disorder is selected from diseases of immune, autoimmune, immunodeficiency or inflammatory origin such as: asthma, COPD, bronchitis, rhinitis, allergy, rheumatoid arthritis, dermatitis, general inflammation (e. g. tendonitis, bursitis, etc. ), inflammatory pain, Crohn's disease, ulcerative colitis, inflammatory bowel syndrome, gastritis, colitis, Alzhiemer's disease, AIDS, severe combined immunodeficiency, viral infections, bacterial infections, acne vulgaris, septic shock, anaphylaxis, antibody mediated rejection, Type I diabetes mellitus, Goodpasture's syndrome, myasthenia gravis, systemic lupus erythematosis. Grave's disease, and systemic sclerosis, familial cold urticaria and Muckle-Wells syndrome.

Brief Description of the Sequences SEQ ID NO: 1 shows the nucleotide and amino acid sequences of human

protein HIPHUM 0000070.

SEQ ID NO : 2 is the amino acid sequence alone of HIPHUM 0000070.

Brief Description of the Figures Figure I shows the relative expression levels of HIPHUM 0000070 in a variety of normal human tissues.

Figure 2 shows the relative expression levels of HIPHUM 0000070 in a variety of immune cells and related tissues. PBMNCs-human peripheral blood mononucleocytes ; PBLs-human peripheral blood lymphocytes; HIV-human

immunodeficiency virus ; HSV-herpes simplex virus.

Figure 3 shows the relative expression levels of HIPHUM 0000070 in diseased brain, osteoarthritis and endothelial cells.

Detailed Description of the Invention Throughout the present specification and the accompanying claims the words "comprise"and"include"and variations such as"comprises","comprising", "includes"and"including"are to be interpreted inclusively. That is, these words are intended to convey the possible inclusion of other elements or integers not specifically recited, where the context allows.

The present invention relates to a human receptor polypeptide having immunomodulatory activity, referred to herein as HIPHUM 0000070, and variants thereof. Sequence information for HIPHUM 0000070 is provided in SEQ ID NO: 1 (nucleotide and amino acid) and in SEQ ID NO: 2. A polypeptide of the invention thus consists essentially of the amino acid sequence of SEQ ID NO: 2 or of a variant of that sequence, or of a fragment of either thereof.

Polypeptides of the invention may be in a substantially isolated form. It will be understood that the polypeptide may be mixed with carriers or diluents which will not interfere with the intended purpose of the polypeptide and still be regarded as substantially isolated. A polypeptide of the invention may also be in a substantially purified form, in which case it will generally comprise the polypeptide in a preparation in which more than 50%, e. g. more than 80%, 90%, 95% or 99%, by

weight of the polypeptide in the preparation is a polypeptide of the invention.

Routine methods, can be employed to purify and/or synthesise the proteins according to the invention. Such methods are well understood by persons skilled in the art, and include techniques such as those disclosed in Sambrook et al, Molecular Cloning: a Laboratory Manual, 2"Edition, CSH Laboratory Press, 1989, the disclosure of which is included herein in its entirety by way of reference.

The term"variant"refers to a polypeptide which has a same essential character or basic biological functionality as HIPHUM 0000070. The essential character of HIPHUM 0000070 can be defined as follows: HIPHUM 0000070 is a receptor polypeptide having immunomodulatory activity. Preferably a variant polypeptide is one which binds to the same ligand as HIPHUM 0000070. Preferably the polypeptide is capable of immunomodulatory activity. A polypeptide having a same essential character as HIPHUM 0000070 may be identified by monitoring for a function the receptor polypeptides having immunomodulatory activity-like receptor selected from an immunomodulatory activity. In particular, effects on humoral immunity and antigen presentation may be monitored. In addition the receptor may play a role in endothelial cell and osteoblast function, and such activity may be monitored to identify a variant of the invention. A variant receptor may be identified by looking for ligand binding. A full length variant polypeptide is preferably one which includes a seven transmembrane region. Preferably, a full length variant polypeptide may couple to G-protein to mediate intracellular responses.

In another aspect of the invention, a variant is one which does not show the same activity as HIPHUM 0000070 but is one which inhibits a basic function of HIPHUM 0000070. For example, a variant polypeptide is one which inhibits immunomodulatory activity of HIPHUM 0000070, for example by binding to HIPHUM 0000070 ligand to prevent activity mediated by ligand binding to HIPHUM 0000070.

Typically, polypeptides with more than about 65% identity preferably at least 80% or at least 90% and particularly preferably at least 95% at least 97% or at least 99% identity, with the amino acid sequences of SEQ ID NO: 2, are considered as variants of the proteins. Such variants may include allelic variants and the deletion, modification or addition of single amino acids or groups of amino acids within the

protein sequence, as long as the peptide maintains a basic biological functionality of the HIPHUM 0000070 receptor.

Amino acid substitutions may be made, for example from 1,2 or 3 to 10,20 or 30 substitutions. The modified polypeptide generally retains activity as a receptor polypeptide having immunomodulatory activity. Conservative substitutions may be made, for example according to the following Table. Amino acids in the same block in the second column and preferably in the same line in the third column may be substituted for each other.

ALIPHATIC G A P I L V Polar-uncharged C S T M N Q Polar-charged D E K R AROMATIC H F W Y Shorter polypeptide sequences are within the scope of the invention. For example, a peptide of at least 20 amino acids or up to 50,60, 70,80, 100,150 or 200 amino acids in length is considered to fall within the scope of the invention as long as it demonstrates a basic biological functionality of HIPHUM 0000070. In particular, but not exclusively, this aspect of the invention encompasses the situation when the protein is a fragment of the complete protein sequence and may represent a ligandbinding region (N-terminal extracellular domain) or an effector binding region (Cterminal intracellular domain). Such fragments can be used to construct chimeric receptors preferably with another 7-transmembrane receptor, more preferably with another member of the family of receptor polypeptides having immunomodulatory activity. Such fragments of HIPHUM 0000070 or a variant thereof can also be used

to raise anti-HIPHUM 0000070 antibodies. In this embodiment the fragment may comprise an epitope of the HIPHUM 0000070 polypeptide and may otherwise not demonstrate the ligand binding or other properties of HIPHUM 0000070.

Polypeptides of the invention may be chemically modified, e. g. posttranslationally modified. For example, they may be glycosylated or comprise modified amino acid residues. They may also be modified by the addition of histidine residues to assist their purification or by the addition of a signal sequence to promote insertion into the cell membrane. Such modified polypeptides fall within the scope of the term"polypeptide"of the invention.

The invention also includes nucleotide sequences that encode for HIPHUM 0000070 or variant thereof as well as nucleotide sequences which are complementary thereto. The nucleotide sequence may be RNA or DNA including genomic DNA, synthetic DNA or cDNA. Preferably the nucleotide sequence is a DNA sequence and most preferably, a cDNA sequence. Nucleotide sequence information is provided in SEQ ID NO: 1. Such nucleotides can be isolated from human cells or synthesised according to methods well known in the art, as described by way of example in Sambrook et al, 1989.

Typically a polynucleotide of the invention comprises a contiguous sequence of nucleotides which is capable of hybridizing under selective conditions to the coding sequence or the complement of the coding sequence of SEQ ID NO: 1.

A polynucleotide of the invention can hydridize to the coding sequence or the complement of the coding sequence of SEQ ID NO: 1 at a level significantly above background. Background hybridization may occur, for example, because of other cDNAs present in a cDNA library. The signal level generated by the interaction between a polynucleotide of the invention and the coding sequence or complement of the coding sequence of SEQ ID NO: 1 is typically at least 10 fold, preferably at least 100 fold, as intense as interactions between other polynucleotides and the coding sequence of SEQ ID NO: 1. The intensity of interaction may be measured, for example, by radiolabelling the probe, e. g. with 32p. Selective hybridisation may typically be achieved using conditions of medium to high stringency. However, such hybridisation may be carried out under any suitable conditions known in the art (see Sambrook et al, 1989. For example, if high stringency is required suitable conditions

include from 0. 1 to 0. 2 x SSC at 60 oc up to 65 OC. If lower stringency is required suitable conditions include 2 x SSC at 60 OC.

The coding sequence of SEQ ID NO: 1 may be modified by nucleotide substitutions, for example from 1,2 or 3 to 10,25, 50 or 100 substitutions. The polynucleotide of SEQ ID NO: 1 may alternatively or additionally be modified by one or more insertions and/or deletions and/or by an extension at either or both ends.

A polynucleotide may include one or more introns, for example may comprise genomic DNA. Additional sequences such as signal sequences which may assist in insertion of the polypeptide in a cell membrane may also be included. The modified polynucleotide generally encodes a polypeptide which has a HIPHUM 0000070 receptor activity. Alternatively, a polynucleotide encodes a ligand-binding portion of a polypeptide or a polypeptide which inhibits HIPHUM 0000070 activity.

Degenerate substitutions may be made and/or substitutions may be made which would result in a conservative amino acid substitution when the modified sequence is translated, for example as shown in the Table above.

A nucleotide sequence which is capable of selectively hybridizing to the complement of the DNA coding sequence of SEQ ID NO: 1 will generally have at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 98% or at least 99% sequence identity to the coding sequence of SEQ ID NO: 1 over a region of at least 20, preferably at least 30, for instance at least 40, at least 60, more preferably at least 100 contiguous nucleotides or most preferably over the full length of SEQ ID NO : 1.

For example the UWGCG Package provides the BESTFIT program which can be used to calculate homology (for example used on its default settings) (Devereux et al (1984) Nucleic Acids Research 12, p387-395). The PILEUP and BLAST algorithms can be used to calculate homology or line up sequences (typically on their default settings), for example as described in Altschul (1993) J. Mol. Evol.

36: 290-300; Altschul et al (1990) J. Mol. Biol. 215: 403-10.

Software for performing BLAST analyses is publicly available through the National Centre for Biotechnology Information (http://www. ncbi. nlm. nih. os/).

This algorithm involves first identifying high scoring sequence pair (HSPs) by identifying short words of length W in the query sequence that either match or satisfy

some positive-valued threshold score T when aligned with a word of the same length in a database sequence. T is referred to as the neighbourhood word score threshold (Altschul et al, 1990). These initial neighbourhood word hits act as seeds for initiating searches to find HSPs containing them. The word hits are extended in both directions along each sequence for as far as the cumulative alignment score can be increased. Extensions for the word hits in each direction are halted when: the cumulative alignment score falls off by the quantity X from its maximum achieved value; the cumulative score goes to zero or below, due to the accumulation of one or more negative-scoring residue alignments ; or the end of either sequence is reached.

The BLAST algorithm parameters W, T and X determine the sensitivity and speed of the alignment. The BLAST program uses as defaults a word length (W) of 11, the BLOSUM62 scoring matrix (see Henikoffand Henikoff (1992) Proc. Natl. Acad Sci. USA 89: 10915-10919) alignments (B) of 50, expectation (E) of 10, M=5, N=4, and a comparison of both strands.

The BLAST algorithm performs a statistical analysis of the similarity between two sequences; see e. g. , Karlin and Altschul (1993) Proc. Natl. Acad. Sci.

USA 90: 5873-5787. One measure of similarity provided by the BLAST algorithm is the smallest sum probability (P (N) ), which provides an indication of the probability by which a match between two nucleotide or amino acid sequences would occur by chance. For example, a sequence is considered similar to another sequence if the smallest sum probability in comparison of the first sequence to the second sequence is less than about 1, preferably less than about 0.1, more preferably less than about 0. 01, and most preferably less than about 0. 001.

Any combination of the above mentioned degrees of sequence identity and minimum sizes may be used to define polynucleotides of the invention, with the more stringent combinations (i. e. higher sequence identity over longer lengths) being preferred. Thus, for example a polynucleotide which has at least 90% sequence identity over 25, preferably over 30 nucleotides forms one aspect of the invention, as does a polynucleotide which has at least 95% sequence identity over 40 nucleotides.

The nucleotides according to the invention have utility in production of the proteins according to the invention, which may take place in vitro, in vivo or ex vivo.

The nucleotides may be involved in recombinant protein synthesis or indeed as

therapeutic agents in their own right, utilised in gene therapy techniques. Nucleotides complementary to those encoding HIPHUM 0000070, or antisense sequences, may also be used in gene therapy.

Polynucleotides of the invention may be used as a primer, e. g. a PCR primer, a primer for an alternative amplification reaction, a probe e. g. labelled with a revealing label by conventional means using radioactive or non-radioactive labels, or the polynucleotides may be cloned into vectors.

Such primers, probes and other fragments will preferably be at least 10, preferably at least 15 or at least 20, for example at least 25, at least 30 or at least 40 nucleotides in length. They will typically be up to 40,50, 60,70, 100 or 150 nucleotides in length. Probes and fragments can be longer than 150 nucleotides in length, for example up to 200,300, 400,500, 600,700 nucleotides in length, or even up to a few nucleotides, such as five or ten nucleotides, short of the coding sequence ofSEQIDNO : 1.

The present invention also includes expression vectors that comprise nucleotide sequences encoding the proteins or variants thereof of the invention. Such expression vectors are routinely constructed in the art of molecular biology and may for example involve the use of plasmid DNA and appropriate initiators, promoters, enhancers and other elements, such as for example polyadenylation signals which may be necessary, and which are positioned in the correct orientation, in order to allow for protein expression. Other suitable vectors would be apparent to persons skilled in the art. By way of further example in this regard we refer to Sambrook et al. 1989.

Polynucleotides according to the invention may also be inserted into the vectors described above in an antisense orientation in order to provide for the production of antisense RNA. Antisense RNA or other antisense polynucleotides may also be produced by synthetic means. Such antisense polynucleotides may be used as test compounds in the assays of the invention or may be useful in a method of treatment of the human or animal body by therapy.

Preferably, a polynucleotide of the invention or for use in the invention in a vector is operably linked to a control sequence which is capable of providing for the expression of the coding sequence by the host cell, i. e. the vector is an expression

vector. The term"operably linked"refers to a juxtaposition wherein the components described are in a relationship permitting them to function in their intended manner.

A regulatory sequence, such as a promoter,"operably linked"to a coding sequence is positioned in such a way that expression of the coding sequence is achieved under conditions compatible with the regulatory sequence.

The vectors may be for example, plasmid, virus or phage vectors provided with a origin of replication, optionally a promoter for the expression of the said polynucleotide and optionally a regulator of the promoter. The vectors may contain one or more selectable marker genes, for example an ampicillin resistence gene in the case of a bacterial plasmid or a resistance gene for a fungal vector. Vectors may be used in vitro, for example for the production of DNA or RNA or used to transfect or transform a host cell, for example, a mammalian host cell. The vectors may also be adapted to be used in vivo, for example in a method of gene therapy.

Promoters and other expression regulation signals may be selected to be compatible with the host cell for which expression is designed. For example, yeast

promoters include S. cerevisiae GAL4 and ADH promoters, S. pombe nmtl and adh promoter. Mammalian promoters include the metallothionein promoter which can be induced in response to heavy metals such as cadmium. Viral promoters such as the SV40 large T antigen promoter or adenovirus promoters may also be used. All these promoters are readily available in the art.

Mammalian promoters, such as -actin promoters, may be used. Tissuespecific promoters are especially preferred. Viral promoters may also be used, for example the Moloney murine leukaemia virus long terminal repeat (MMLV LTR), the rous sarcoma virus (RSV) LTR promoter, the SV40 promoter, the human cytomegalovirus (CMV) IE promoter, adenovirus, HSV promoters (such as the HSV IE promoters), or HPV promoters, particularly the HPV upstream regulatory region (URR). Viral promoters are readily available in the art.

The vector may further include sequences flanking the polynucleotide giving rise to polynucleotides which comprise sequences homologous to eukaryotic genomic sequences, preferably mammalian genomic sequences, or viral genomic sequences. This will allow the introduction of the polynucleotides of the invention into the genome of eukaryotic cells or viruses by homologous recombination. In

particular, a plasmid vector comprising the expression cassette flanked by viral sequences can be used to prepare a viral vector suitable for delivering the polynucleotides of the invention to a mammalian cell. Other examples of suitable viral vectors include herpes simplex viral vectors and retroviruses, including lentiviruses, adenoviruses, adeno-associated viruses and HPV viruses. Gene transfer techniques using these viruses are known to those skilled in the art. Retrovirus vectors for example may be used to stably integrate the polynucleotide giving rise to the polynucleotide into the host genome. Replication-defective adenovirus vectors by contrast remain episomal and therefore allow transient expression.

The invention also includes cells that have been modified to express the HIPHUM 0000070 polypeptide or a variant thereof. Such cells include transient, or preferably stable higher eukaryotic cell lines, such as mammalian cells or insect cells, using for example a baculovirus expression system, lower eukaryotic cells, such as yeast or prokaryotic cells such as bacterial cells. Particular examples of cells which may be modified by insertion of vectors encoding for a polypeptide according to the invention include mammalian HEK293T, CHO, HeLa and COS cells. Preferably the cell line selected will be one which is not only stable, but also allows for mature glycosylation and cell surface expression of a polypeptide. Expression may be achieved in transformed oocytes. A polypeptide of the invention may be expressed in cells of a transgenic non-human animal, preferably a mouse. A transgenic nonhuman animal expressing a polypeptide of the invention is included within the scope of the invention. A polypeptide of the invention may also be expressed in Xenopus laevis oocytes or melanophores, in particular for use in an assay of the invention.

According to another aspect, the present invention also relates to antibodies, specific for a polypeptide of the invention. Such antibodies are for example useful in purification, isolation or screening methods involving immunoprecipitation techniques or, indeed, as therapeutic agents in their own right.

Antibodies may be raised against specific epitopes of the polypeptides according to the invention. Such antibodies may be used to block ligand binding to the receptor. An antibody, or other compound,"specifically binds"to a protein when it binds with preferential or high affinity to the protein for which it is specific but does substantially bind not bind or binds with only low affinity to other proteins. A

variety of protocols for competitive binding or immunoradiometric assays to determine the specific binding capability of an antibody are well known in the art (see for example Maddox et al, J. Exp. Med. 158,1211-1226, 1993). Such immunoassays typically involve the formation of complexes between the specific protein and its antibody and the measurement of complex formation.

Antibodies of the invention may be antibodies to human polypeptides or fragments thereof. For the purposes of this invention, the term"antibody", unless specified to the contrary, includes fragments which bind a polypeptide of the invention. Such fragments include Fv, F (ab') and F (ab') 2 fragments, as well as single chain antibodies. Furthermore, the antibodies and fragment thereof may be chimeric antibodies, CDR-grafted antibodies or humanised antibodies.

Antibodies may be used in a method for detecting polypeptides of the invention in a biological sample, which method comprises: I providing an antibody of the invention; II incubating a biological sample with said antibody under conditions which allow for the formation of an antibody-antigen complex; and III determining whether antibody-antigen complex comprising said antibody is formed.

A sample may be for example a tissue extract, blood, serum and saliva.

Antibodies of the invention may be bound to a solid support and/or packaged into kits in a suitable container along with suitable reagents, controls, instructions, etc.

Antibodies may be linked to a revealing label and thus may be suitable for use in methods of wvo HIPHUM 0000070 imaging.

Antibodies of the invention can be produced by any suitable method. Means for preparing and characterising antibodies are well known in the art, see for example Harlow and Lane (1988)"Antibodies : A Laboratory Manual", Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY. For example, an antibody may be produced by raising antibody in a host animal against the whole polypeptide or a fragment thereof, for example an antigenic epitope thereof, herein after the "immunogen".

A method for producing a polyclonal antibody comprises immunising a suitable host animal, for example an experimental animal, with the immunogen and

isolating immunoglobulins from the animal's serum. The animal may therefore be inoculated with the immunogen, blood subsequently removed from the animal and the IgG fraction purified.

A method for producing a monoclonal antibody comprises immortalising cells which produce the desired antibody. Hybridoma cells may be produced by fusing spleen cells from an inoculated experimental animal with tumour cells (Kohler and Milstein (1975) Nature 256,495-497).

An immortalized cell producing the desired antibody may be selected by a conventional procedure. The hybridomas may be grown in culture or injected intraperitoneally for formation of ascites fluid or into the blood stream of an allogenic host or immunocompromised host. Human antibody may be prepared by in vitro immunisation of human lymphocytes, followed by transformation of the lymphocytes with Epstein-Barr virus.

For the production of both monoclonal and polyclonal antibodies, the experimental animal is suitably a goat, rabbit, rat or mouse. If desired, the immunogen may be administered as a conjugate in which the immunogen is coupled, for example via a side chain of one of the amino acid residues, to a suitable carrier.

The carrier molecule is typically a physiologically acceptable carrier. The antibody obtained may be isolated and, if desired, purified.

An important aspect of the present invention is the use of polypeptides according to the invention in screening methods. The screening methods may be used to identify substances that bind to receptor polypeptides having immunomodulatory activity and in particular which bind to HIPHUM 0000070 such as a ligand for the receptor. Screening methods may also be used to identify agonists or antagonists which may modulate receptor polypeptides having immunomodulatory activity, inhibitors or activators of HIPHUM 0000070 activity, and/or agents which up-regulate or down-regulate HIPHUM 0000070 expression.

Any suitable format may be used for the assay. In general terms such screening methods may involve contacting a polypeptide of the invention with a test substance and monitoring for binding of the test substance to the polypeptide or measuring receptor activity. A polypeptide of the invention may be incubated with a test substance. Modulation of receptor polypeptides having immunomodulatory

activity may be determined. In a preferred aspect, the assay is a cell-based assay. Preferably the assay may be carried out in a single well of a microtitre plate. Assay formats which allow high throughput screening are preferred.

Modulator activity can be determined by contacting cells expressing a polypeptide of the invention with a substance under investigation and by monitoring an effect mediated by the polypeptide. The cells expressing the polypeptide may be in vitro or in vivo. The polypeptide of the invention may be naturally or recombinantly expressed. Preferably, the assay is carried out in vitro using cells expressing recombinant polypeptide. Preferably, control experiments are carried out on cells which do not express the polypeptide of the invention to establish whether the observed responses are the result of activation of the polypeptide.

The binding of a test substance to a polypeptide of the invention can be determined directly. For example, a radiolabelled test substance can be incubated with the polypeptide of the invention and binding of the test substance to the polypeptide can be monitored. Typically, the radiolabelled test substance can be incubated with cell membranes containing the polypeptide until equilibrium is reached. The membranes can then be separated from a non-bound test substance and dissolved in scintillation fluid to allow the radioactive content to be determined by scintillation counting. Non-specific binding of the test substance may also be determined by repeating the experiment in the presence of a saturating concentration of a non-radioactive ligand.

Assays may be carried out using cells expressing HIPHUM 0000070, and incubating such cells with the test substance optionally in the presence of HIPHUM 0000070 ligand. Alternatively an antibody may be used to complex HIPHUM 0000070 and thus mediate HIPHUM 0000070 activity. Test substances may then be added to assess the effect on such activity. Cells expressing HIPHUM 0000070 constitutively may be provided for use in assays for HIPHUM 0000070 function.

Such constitutively expressed HIPHUM 0000070 may demonstrate HIPHUM 0000070 activity in the absence of ligand binding. Additional test substances may be introduced in any assay to look for inhibitors of ligand binding or inhibitors of HIPHUM 0000070-mediated activity.

In preferred aspects, a host cell is provided expressing the polypeptide and

containing a G-protein coupled pathway responsive reporter construct. The host cell is treated with a substance under test for a defined time. The expression of the. reporter gene, such as SP alkaline phosphatase or luciferase is assayed. The assay enables determination of whether the compound modulates the induction of the Gprotein coupled pathway by HIPHUM 0000070 in target cells.

Assays may also be carried out to identify modulators of receptor-shedding.

A polypeptide of the invention can be cleaved from the cell surface. Shedding the receptor would act to down regulate receptor signalling. Thus, cell-based assays may be used to screen for compounds which promote or inhibit receptor-shedding.

Assays may also be carried out to identify substances which modify HIPHUM 0000070 receptor expression, for example substances which up-or downregulate expression. Such assays may be carried out for example by using antibodies for HIPHUM 0000070 to monitor levels of HIPHUM 0000070 expression. Other assays which can be used to monitor the effect of a test substance on HIPHUM 0000070 expression include using a reporter gene construct driven by the HIPHUM 0000070 regulatory sequences as the promoter sequence and monitoring for expression of the reporter polypeptide. Further possible assays could utilise membrane fractions from overexpression of HIPHUM 0000070 polypeptide either in

X laevis oocytes or cell lines such as HEK293, CHO, COS7 and HeLa cells and assessment of displacement of a radiolabelled ligand.

Additional control experiments may be carried out. Assays may also be carried out using known ligands of other receptor polypeptides having immunomodulatory activity to identify ligands which are specific for polypeptides of the invention. Preferably, the assays of the invention are carried out under conditions which would result in G-protein coupled pathway mediated activity in the absence of the test substance, to identify inhibitors or activators of receptor polypeptides having immunomodulatory activity, or agents which inhibit ligand-induced receptor polypeptides having immunomodulatory activity. An assay of the invention may be carried out using a known agonist or antagonist to provide a comparison with a compound under test.

Typically, receptor activity can be monitored indirectly for example by measuring a G-protein coupled readout. G-protein coupled readout can typically be

monitored using an electrophysiological method to determine the activity of Gprotein regulated Ca2+ or K+ channels or by using a fluorescent dye to measure changed in intracellular Ca2+ levels. The receptor could be coupled to Gs, Gq, Gi and/or Go. Thus cAMP or GTP (S levels or activity, calcium mobilization, inositol triphosphate generation and protein kinase C activation may be monitored.

Following receptor stimulation, cyclic AMP accumulation can be measured for example in forskolin stimulated CHO cells transformed with the HIPHUM 0000070 receptor either directly, or indirectly by monitoring the expression of cotransfected reporter gene, the expression of which will be controlled by cyclic AMP response elements.

Xenopus dermal melanophores aggregate or disperse pigment in response to the activation or inhibition of G-protein coupled receptors. This feature can be exploited as an assay for receptor activation or inhibition if a specific G-protein coupled receptor is exogenously expressed.

HIPHUM 0000070 receptor is likely to couple to G-protein with consequent hydrolysis of GTP. Accumulation of a labelled GTP stable analogue can be measured utilising membrane fractions from overexpression of HIPHUM 0000070 receptor either inX laevis oocytes or cell lines such as HEK293, CHO, COS7, HeLa on exposure to agonist ligand.

G-protein coupled receptors have been shown to activate MAPK signalling pathways. Cell lines overexpressing the receptor polypeptides having immunomodulatory activity-like receptor of the invention with MAPK reporter genes may be utilised as assays for receptor activation or inhibition. The receptor polypeptides having immunomodulatory activity-like receptor of the invention may be heterologously expressed in modified yeast strains containing multiple reporter genes, such as FUS1-HIS3 and FUSl-lacZ, each linked to an endogenous MAPK cascade-based signal transduction pathway. This pathway is normally linked to pheromone receptors, but can be coupled to foreign receptors by replacement of the yeast G-protein with yeast/mammalian G protein chimeras. Strains may also contain two further gene deletions, i. e. deletions of SST2 and FART, to potentiate the assay.

Ligand activation of the heterologous receptor can be monitored using the reporter genes, for example either as cell growth in the absence of histidine or with a substrate

of beta-galactosidase (lacZ).

Suitable test substances which can be tested in the above assays include combinatorial libraries, defined chemical entities and compounds, peptide and peptide mimetics, oligonucleotides and natural product libraries, such as display (e. g. phage display libraries) and antibody products.

Typically, organic molecules will be screened, preferably small organic molecules which have a molecular weight of from 50 to 2500 daltons. Candidate products can be biomolecules including, saccharides, fatty acids, steroids, purines, pyrimidines, derivatives, structural analogs or combinations thereof Candidate agents are obtained from a wide variety of sources including libraries of synthetic or natural compounds. Known pharmacological agents may be subjected to directed or random chemical modifications, such as acylation, alkylation, esterification, amidification, etc. to produce structural analogs.

Test substances may be used in an initial screen of, for example, 10 substances per reaction, and the substances of these batches which show inhibition or activation tested individually. Test substances may be used at a concentration of

from InM to 1OOOuM, preferably from luM to 1OOuM, more preferably from 1 to lOpM. Preferably, the activity of a test substance is compared to the activity shown by a known activator or inhibitor. A test substance which acts as an inhibitor may produce a 50% inhibition of activity of the receptor. Alternatively a test substance which acts as an activator may produce 50% of the maximal activity produced using a known activator.

Another aspect of the present invention is the use of polynucleotides encoding the HIPHUM 0000070 polypeptides of the invention to identify mutations in HIPHUM 0000070 genes which may be implicated in human disorders.

Identification of such mutations may be used to assist in diagnosis or susceptibility to such disorders and in assessing the physiology of such disorders. Polynucleotides may also be used in hybridisation studies to monitor for up-or down-regulation of HIPHUM 0000070 expression. Polynucleotides such as SEQ ID NO: 1 or fragments thereof may be used to identify allelic variants, genomic DNA and species variants.

The present invention provides a method for detecting variation in the

expressed products encoded by HIPHUM 0000070 genes. This may comprise determining the level of an HIPHUM 0000070 expressed in cells or determining specific alterations in the expressed product. Sequences of interest for diagnostic purposes include, but are not limited to, the conserved portions as identified by sequence similarity and conservation of intron/exon structure. The diagnosis may be performed in conjunction with kindred studies to determine whether a mutation of interest co-segregates with disease phenotype in a family.

Diagnostic procedures may be performed on polynucleotides isolated from an individual or alternatively, may be performed in situ directly upon tissue sections (fixed and/or frozen) of patient tissue obtained from biopsies or resections, such that no nucleic acid purification is necessary. Appropriate procedures are described in, for example, Nuovo, G. J., 1992,"PCR In Situ Hybridization: Protocols And Applications", Raven Press, NY). Such analysis techniques include, DNA or RNA blotting analyses, single stranded conformational polymorphism analyses, in situ hybridization assays, and polymerase chain reaction analyses. Such analyses may reveal both quantitative aspects of the expression pattern of a HIPHUM 0000070, and qualitative aspects of HIPHUM 0000070 expression and/or composition.

Alternative diagnostic methods for the detection of HIPHUM 0000070 nucleic acid molecules may involve their amplification, e. g. by PCR (the experimental embodiment set forth in U. S. Patent No. 4,683, 202), ligase chain reaction (Barany, 1991, Proc. Natl. Acad. Sci. USA 88: 189-193), self sustained sequence replication (Guatelli et al., 1990, Proc. Natl. Acad. Sci. USA 87: 18741878), transcriptional amplification system (Kwoh et al., 1989, Proc. Natl. Acad. Sci.

15 USA 86: 1173-1177), Q-Beta Replicase (Lizardi et al., 1988, Bio/Technology 6: 1197) or any other nucleic acid amplification method, followed by the detection of the amplified molecules using techniques well known to those of skill in the art.

These detection schemes are especially useful for the detection of nucleic acid molecules if such molecules are present in very low numbers.

Particularly suitable diagnostic methods are chip-based DNA technologies such as those described by Hacia et al., 1996, Nature Genetics 14: 441-447 and Shoemaker et al., 1996, Nature Genetics 14: 450-456. Briefly, these techniques involve quantitative methods for analyzing large numbers of nucleic acid sequence

targets rapidly and accurately. By tagging with oligonucleotides or using fixed probe arrays, one can employ chip technology to segregate target molecules as high density arrays and screen these molecules on the basis of hybridization.

Following detection, the results seen in a given patient may be compared with a statistically significant reference group of normal patients and patients that have HIPHUM 0000070 related pathologies. In this way, it is possible to correlate the amount or kind of HIPHUM 0000070 encoded product detected with various clinical states or predisposition to clinical states.

Another aspect of the present invention is the use of the substances that have been identified by screening techniques referred to above in the treatment of disease states, which are responsive to regulation of receptor polypeptides having immunomodulatory activity. The treatment may be therapeutic or prophylactic. The condition of a patient suffering from such a disease state can thus be improved.

In particular, such substances may be used in the treatment of diseases of immune, autoimmune, immunodeficiency or inflammatory origin such as: asthma, COPD, bronchitis, rhinitis, allergy, rheumatoid arthritis, dermatitis, general inflammation (e. g. tendonitis, bursitis, etc. ), inflammatory pain, Crohn's disease, ulcerative colitis, inflammatory bowel syndrome, gastritis, colitis, Alzhiemer's disease, AIDS, severe combined immunodeficiency, viral infections, bacterial infections, acne vulgaris, septic shock, anaphylaxis, antibody mediated rejection, Type I diabetes mellitus, Goodpasture's syndrome, myasthenia gravis, systemic lupus erythematosis, Grave's disease, and systemic sclerosis, familial cold urticaria and Muckle-Wells syndrome.

Additional disease states that may be treated include diseases related to angiogenesis such as diabetic retinopathy, tumor metastasis, rheumatoid arthritis, osteoarthritis, hemangiomas, psoriasis, peripheral vascular disease, ischemic heart disease, arteriosclerosis, neovascular glaucoma, endometriosis, osteoporosis, osteopetrosis, osteoarthitis and any other musculoskeletal disorder, neurodegenerative diseases such as Alzheimer's disease, amyotrophic lateral sclerosis, myotonic dystrophy, Huntington's chorea, Parkinson's disease, spinocerebellar ataxia, cerebellar degeneration, ataxia, tremors, akathesia, dyskinesias, loss of coordinated movement, palsy such as Cerebral, Bell's or progressive supranuclear palsy.

Substances identified according to the screening methods outlined above may be formulated with standard pharmaceutically acceptable carriers and/or excipients as is routine in the pharmaceutical art. For example, a suitable substance may be dissolved in physiological saline or water for injections. The exact nature of a formulation ill depend upon several factors including the particular substance to be administered and the desired route of administration. Suitable types of formulation

are fully described in Remington's Pharmaceutical Sciences, Mack Publishing Company, Eastern Pennsylvania, 17th Ed. 1985, the disclosure of which is included herein of its entirety by way of reference.

The substances may be administered by enteral or parenteral routes such as via oral, buccal, anal, pulmonary, intravenous, intra-arterial, intramuscular, intraperitoneal, topical or other appropriate administration routes.

A therapeutically effective amount of a modulator is administered to a patient. The dose of a modulator may be determined according to various parameters, especially according to the substance used ; the age, weight and condition of the patient to be treated; the route of administration; and the required regimen. A physician will be able to determine the required route of administration and dosage for any particular patient. A typical daily dose is from about 0.1 to 50 mg per kg of body weight, according to the activity of the specific modulator, the age, weight and conditions of the subject to be treated, the type and severity of the degeneration and the frequency and route of administration. Preferably, daily dosage levels are from 5 mg to 2 g.

Nucleic acid encoding HIPHUM 0000070 or a variant thereof which inhibits HIPHUM 0000070 activity may be administered to the mammal. Nucleic acid, such as RNA or DNA, and preferably, DNA, is provided in the form of a vector, such as the polynucleotides described above, which may be expressed in the cells of the mammal.

Nucleic acid encoding the polypeptide may be administered by any available technique. For example, the nucleic acid may be introduced by needle injection, preferably intradermally, subcutaneously or intramuscularly. Alternatively, the nucleic acid may be delivered directly across the skin using a nucleic acid delivery device such as particle-mediated gene delivery. The nucleic acid may be

administered topically to the skin, or to mucosal surfaces for example by intranasal, oral, intravaginal or intrarectal administration.

Uptake of nucleic acid constructs may be enhanced by several known transfection techniques, for example those including the use of transfection agents.

Examples of these agents includes cationic agents, for example, calcium phosphate and DEAE-Dextran and lipofectants, for example, lipofectam and transfectam. The dosage of the nucleic acid to be administered can be altered. Typically the nucleic acid is administered in the range of Ipg to Img, preferably to Ipg to 10jug nucleic acid for particle mediated gene delivery and I Ogg to Img for other routes.

The following Examples illustrate the invention.

Example 1: Characterisation of the sequence A receptor polypeptides having immunomodulatory activity, designated as HIPHUM 0000070 has been identified. The nucleotide and amino acid sequences of the receptor have been determined. These are set out below in SEQ ID NOs: 1 and 2.

Suitable primers and probes were designed and used to analyse tissue expression.

HIPHUM 0000070 was found to be primarily expressed in a wide variety of tissues tested (figure 1). The receptor was expressed in all immune cells tested including T cells, B cells, monocytes and dendriditc cells (figure 2). Hiphum 70 was upregulated in Hepatitis B-infected cells and in lung from asthma and COPD patients (Figure 2).

Hiphum 70 was expressed in endothelial cells, RA synovium and osteoblasts (Figures 2 and 3). Receptor expression was upregulated in frontal cortex from Alzheimer's, Huntington's chorea and myotonic dystrophy patients (Figure 3).

Hiphum 70 was down-regulated in cartilage from osteoarthritic knee (Figure 3).

The chromosomal localization was also mapped. Human HIPHUM 0000070 has been mapped to lq44 as determined by electronic PCR. Familial cold urticaria and Muckle-Wells syndrome map to this locus on chromosome 1. In familial cold urticaria, after exposure to cold the patient develops urticarial wheals, pain and swelling of joints, chills, and fever. In patients with Muckle-wells syndrome, patients present with a syndrome of urticaria, deafness and amyloidosis..

Example 2: Screening for substances which exhibit protein modulating activity Mammalian cells, such as HEK293, CHO and COS7 cells, over-expressing a

polypeptide of the invention are generated for screening purposes. 96 and 384 well plate, high throughput screens (HTS) are employed using fluorescence based calcium indicator molecules, including but not limited to dyes such as Fura-2, Fura-Red, Fluo 3 and Fluo 4 (Molecular Probes). Secondary screening involves the same technology. Tertiary screens involve the study of modulators in rat, mouse and guinea-pig models of disease relevant to the target.

A brief screening assay protocol is as follows : Mammalian cells stably over-expressing a polypeptide of the invention are cultured in black wall, clear bottom, tissue culture-coated, 96 or 384 well plates with a volume of 100111 cell culture medium in each well 3 days before use in a FLIPR (Fluorescence Imaging Plate Reader-Molecular Devices). Cells are incubated with 4uM FLUO-3AM at 30 C in 5% C02 for 90 mins and then washed once in Tyrodes buffer containing 3mM probenecid. Basal fluorescence is determined prior to addition of test substances. The polypeptide is activated upon the addition of a known agonist. Activation results in an increase in intracellular calcium which can be measured directly in the FLIPR. For antagonist studies, substances are preincubated with the cells for 4 minutes following dye loading and washing and fluorescence measured for 4 minutes. Agonists are then added and cell fluorescence measured for a further 1 minute.

Assays may also be carried out as follows:

Gs-coupled receptors are expressed and assayed in mammalian cells which express the 6xCRE-luciferase reporter gene such as CHO cells. Gq-coupled and Gicoupled receptors are expressed and assayed in mammalian cells which express the Gal4/Elk-1 chimeric protein and 5xUAS-luciferase reporter gene. Cells are propagated in either in suspension or adherent cultures.

For adherent culture, cells are propagated in T225 flasks in DMEM/F12 containing 5% fetal bovine serum and 1 mM glutamine. Forty-eight hours prior to assay, cells are harvested with 2 ml of 0.05% trypsin, washed with complete medium and plated at a concentration of 4,000 cells/well in complete medium. Sixteen hours prior to the assay, the medium is removed from the cells and replaced with 90 gl/well of serum-free DMEM/F12. At the time of the assay, test substances are added to the

wells at a final concentration of 10 uM and the plates are incubated for four hours at 37OC in a cell culture incubator. The medium is aspirated by vacuum followed by the addition of 50 al of a 1 : 1 mixture of LucLite and dPBS/1 mM CaCl2/l mM MgCl. Plates are sealed and subjected to dark adaptation at room temperature for 10 minutes before luciferase activity is quantitated on a TopCounf"microplate scintillation counter (Packard) using 3 seconds/well count time.

For suspension cultures, cells are propagated in Excel 301 medium containing 5% FBS and 2 mM glutamine at a minimum of 1x105 cells/ml for one week. Sixteen hours prior to an assay, cells are removed from suspension by centrifugation and resuspended in serum-free Excel 301 at a concentration of in106 cells/ml. At the time of assay, the cells are resuspended in serum-free DMEM/F12 at a concentration of 50,000 cells/ml. 100 l/well or 50 l/well of this suspension is pipetted into black 96-well or 384-well plates, respectively. The 96-well and 384-well plate contained 1 ul or 0.5 p. 1 agonist compounds in 100% DMSO at a final concentration of 10 uM.

A Multidrop S20 cell dispenser is used to dispense cells into either 96-or 384-well plates. The reminder of the assay is the same as described for adherent culture above.

Xenopus oocyte expression Adult female Xenopus laevis (Blades Biologicals) are anaesthetised using 0.2% tricaine (3-aminobenzoic acid ethyl ester), killed and the ovaries rapidly removed. Oocytes are then de-folliculated by collagenase digestion (Sigma type I, 1.5 mg ml-1) in divalent cation-free OR2 solution (82.5mM NaCl, 2.5mM KCI, 1.2mM NaH2PO4, 5mM HEPES ; pH 7.5 at 25OC). Single stage V and VI oocytes are transferred to ND96 solution (96mM NaCl, 2mM KCI, 1mM MgCl, 5mM HEPES, 2.5mM sodium pyruvate; pH 7.5 at 25OC) which contains 50 g mol-'gentamycin and stored at 18 C.

The EDG-like receptor (in pcDNA3, Invitrogen) is linearised and transcribed

to RNA using T7 (Promega Wizard kit). m'G (5') pp (5') GTP capped CERNA is injected into oocytes (20-50ng per oocyte) and whole-cell currents are recorded using two-microelectrode voltage-clamp (Geneclamp amplifier, Axon instruments Inc.) 3 to 7 days post-RNA injection. Microelectrodes have a resistance of 0. 5 to 2MQ when

filled with 3M KCI.

Melanophore screens may be carried out as follows: Modified or unmodified receptors are expressed in melanophores using appropriate vector constructs including pJG3.6. The expressed receptors are then screened for Gs, Gq, Gi or Go activity. When a ligand binds to a Gs-coupled receptor, it activates adenylyl cyclase that in turn activates protein kinase A. This results in the initiation of phosphorylation events that cause the melanosomes to disperse. When a 0,-coupled receptor is activated, it inhibits adenylyl cyclase which in turn reverses the pigment dispersion process to result in aggregation. When a Gqcoupled receptor is activated, it activates phospholipase C, which in turn activates protein kinase C. This results in the initiation of phosphorylation events to cause melanosome dispersion. The expressed receptors can be screened in agonist, antagonist or constitutive modes using bead-based lawn format or 96-well, 384-well or 1536-well formats.

Melanophores are grown in conditioned fibroblast medium (CFM) at room temperature. After harvesting the cells with trypsin/EDTA, approximately 6 to 10 million cells are electroporated with relevant receptor-expression vectors at 475 V, 425 uFd, 720 ohms. The transfected cells are then plated into T225 flasks and are incubated for 24 hours. Cells are then harvested and plated into assay plates and incubated for 24 hours. Test substances are added to wells at 10 uM final concentration and 30-120 minutes later the dispersion or aggregation is measured using an SLT Spectra plate reader. For dispersion assays, cells are first treated with 2 nM melatonin in assay buffer (0.7X L15/0. 1% BSA) for 60 minutes before addition of test compounds. For aggregation assays, CFM is replaced with the assay buffer and cells are incubated for 60 minutes before addition of test compounds.

SEQUENCE LISTING

< 110 > GLAXO GROUP LIMITED < 120 > PROTEIN < 130 > P80201 SER < 140 > < 141 > < 160 > 2 < 170 > PatentIn Ver. 2. 1 < 210 > 1 < 211 > 1209 < 212 > DNA < 213 > Homo sapiens < 220 > < 221 > CDS < 222 > (1).. (1209) < 400 > 1 atg tac teg ggg aac cgc age ggc ggc cac ggc tac tgg gac ggc ggc 48 Met Tyr Ser Gly Asn Arg Ser Gly Gly His Gly Tyr Trp Asp Gly Gly 1 5 10 15 ggg gcc gcg ggc get gag ggg ccg gcg ccg gcg ggg aca ctg age ccc 96 Gly Ala Ala Gly Ala Glu Gly Pro Ala Pro Ala Gly Thr Leu Ser Pro 20 25 30 gcg ccc etc ttc age ccc ggc ace tac gag cgc ctg gcg ctg ctg ctg 144 Ala Pro Leu Phe Ser Pro Gly Thr Tyr Glu Arg Leu Ala Leu Leu Leu 35 40 45 ggc tee att ggg ctg ctg ggc gtc ggc aac aac ctg ctg gtg etc gtc 192 Gly Ser Ile Gly Leu Leu Gly Val Gly Asn Asn Leu Leu Val Leu Val 50 55 60 ctc tac tac aag ttc cag egg etc cgc act ccc act cac etc etc ctg 240 Leu Tyr Tyr Lys Phe Gln Arg Leu Arg Thr Pro Thr His Leu Leu Leu 65 70 75 80 gtc aac ate age etc age gac ctg ctg gtg tee etc ttc ggg gtc ace 288

Val Asn Ile Ser Leu Ser Asp Leu Leu Val Ser Leu Phe Gly Val Thr 85 90 95 ttt ace ttc gtg tee tgc ctg agg aac ggc tgg gtg tgg gac ace gtg 336 Phe Thr Phe Val Ser Cys Leu Arg Asn Gly Trp Val Trp Asp Thr Val 100 105 110 ggc tgc gtg tgg gac ggg ttt age ggc age etc ttc ggg att gtt tee 384 Gly Cys Val Trp Asp Gly Phe Ser Gly Ser Leu Phe Gly Ile Val Ser 115 120 125 att gee ace cta ace gtg ctg gcc tat gaa cgt tac att cgc gtg gtc 432 Ile Ala Thr Leu Thr Val Leu Ala Tyr Glu Arg Tyr Ile Arg Val Val 130 135 140 cat gcc aga gtg ate aat ttt tee tgg gcc tgg agg gcc att ace tac 480 His Ala Arg Val Ile Asn Phe Ser Trp Ala Trp Arg Ala Ile Thr Tyr 145 150 155 160 ate tgg etc tac tea ctg gcg tgg gca gga gca cct etc ctg gga tgg 528 Ile Trp Leu Tyr Ser Leu Ala Trp Ala Gly Ala Pro Leu Leu Gly Trp 165 170 175 aac agg tac ate ctg gac gta cac gga cta ggc tgc act gtg gac tgg 576 Asn Arg Tyr Ile Leu Asp Val His Gly Leu Gly Cys Thr Val Asp Trp 180 185 190 aaa tee aag gat gcc aac gat tee tee ttt gtg ctt ttc tta ttt ctt 624 Lys Ser Lys Asp Ala Asn Asp Ser Ser Phe Val Leu Phe Leu Phe Leu 195 200 205 ggc tgc ctg gtg gtg ccc ctg ggt gtc ata gcc cat tgc tat ggc cat 672 Gly Cys Leu Val Val Pro Leu Gly Val Ile Ala His Cys Tyr Gly His 210 215 220 att cta tat tee att cga-atg ctt cgt tgt gtg gaa gat ctt cag aca 720 Ile Leu Tyr Ser Ile Arg Met Leu Arg Cys Val Glu Asp Leu Gln Thr 225 230 235 240 att caa gtg ate aag att tta aaa tat gaa aag aaa ctg gcc aaa atg 768 Ile Gln Val Ile Lys Ile Leu Lys Tyr Glu Lys Lys Leu Ala Lys Met 245 250 255 tgc ttt tta atg ata ttc ace ttc ctg gtc tgt tgg atg cct tat ate 816 Cys Phe Leu Met Ile Phe Thr Phe Leu Val Cys Trp Met Pro Tyr Ile 260 265 270 gtg ate tgc ttc ttg gtg gtt aat ggt cat ggt cac ctg gtc act cca 864 Val Ile Cys Phe Leu Val Val Asn Gly His Gly His Leu Val Thr Pro 275 280 285 aca ata tct att gtt teg tac etc ttt get aaa teg aac act gta tac 912 Thr Ile Ser Ile Val Ser Tyr Leu Phe Ala Lys Ser Asn Thr Val Tyr 290 295 300 aat cca gtg att tat gtc ttc atg ate aga aag ttt cga aga tee ctt 960 Asn Pro Val Ile Tyr Val Phe Met Ile Arg Lys Phe Arg Arg Ser Leu

305 310 315 320 ttg cag ctt ctg tgc etc cga ctg ctg agg tgc cag agg cct get aaa 1008 Leu Gln Leu Leu Cys Leu Arg Leu Leu Arg Cys Gln Arg Pro Ala Lys 325 330 335 gac cta cca gca get gga agt gaa atg cag ate aga ccc att gtg atg 1056 Asp Leu Pro Ala Ala Gly Ser Glu Met Gln Ile Arg Pro Ile Val Met 340 345 350 tea cag aaa gat ggg gac agg cca aag aaa aaa gtg act ttc aac tct 1104 Ser Gln Lys Asp Gly Asp Arg Pro Lys Lys Lys Val Thr Phe Asn Ser 355 360 365 tct tee ate att ttt ate ate ace agt gat gaa tea ctg tea gtt gac 1152 Ser Ser Ile Ile Phe Ile Ile Thr Ser Asp Glu Ser Leu Ser Val Asp 370 375 380 gac age gac aaa ace aat ggg tee aaa gtt gat gta ate caa gtt cgt 1200 Asp Ser Asp Lys Thr Asn Gly Ser Lys Val Asp Val Ile Gln Val Arg 385 390 395 400 cct ttg tag 1209 Pro Leu < 210 > 2 < 211 > 402 < 212 > PRT < 213 > Homo sapiens < 400 > 2 Met Tyr Ser Gly Asn Arg Ser Gly Gly His Gly Tyr Trp Asp Gly Gly 15 10 15 Gly Ala Ala Gly Ala Glu Gly Pro Ala Pro Ala Gly Thr Leu Ser Pro 20 25 30 Ala Pro Leu Phe Ser Pro Gly Thr Tyr Glu Arg Leu Ala Leu Leu Leu 35 40 45 Gly Ser Ile Gly Leu Leu Gly Val Gly Asn Asn Leu Leu Val Leu Val 50 55 60 Leu Tyr Tyr Lys Phe Gln Arg Leu Arg Thr Pro Thr His Leu Leu Leu 65 70 75 80 Val Asn Ile Ser Leu Ser Asp Leu Leu Val Ser Leu Phe Gly Val Thr 85 90 95 Phe Thr Phe Val Ser Cys Leu Arg Asn Gly Trp Val Trp Asp Thr Val 100 105 110 Gly Cys Val Trp Asp Gly Phe Ser Gly Ser Leu Phe Gly Ile Val Ser 115 120 125 Ile Ala Thr Leu Thr Val Leu Ala Tyr Glu Arg Tyr Ile Arg Val Val

130 135 140 His Ala Arg Val Ile Asn Phe Ser Trp Ala Trp Arg Ala lie Thr Tyr 145 150 155 160 Ile Trp Leu Tyr Ser Leu Ala Trp Ala Gly Ala Pro Leu Leu Gly Trp 165 170 175 Asn Arg Tyr Ile Leu Asp Val His Gly Leu Gly Cys Thr Val Asp Trp 180 185 190 Lys Ser Lys Asp Ala Asn Asp Ser Ser Phe Val Leu Phe Leu Phe Leu 195 200 205

Gly Cys Leu Val Val Pro Leu Gly Val Ile Ala His Cys Tyr Gly His 210 215 220 Ile Leu Tyr Ser Ile Arg Met Leu Arg Cys Val Glu Asp Leu Gln Thr 225 230 235 240 Ile Gln Val Ile Lys Ile Leu Lys Tyr Glu Lys Lys Leu Ala Lys Met 245 250 255 Cys Phe Leu Met Ile Phe Thr Phe Leu Val Cys Trp Met Pro Tyr Ile 260 265 270 Val Ile Cys Phe Leu Val Val Asn Gly His Gly His Leu Val Thr Pro 275 280 285 Thr Ile Ser Ile Val Ser Tyr Leu Phe Ala Lys Ser Asn Thr Val Tyr 290 295 300 Asn Pro Val Ile Tyr Val Phe Met Ile Arg Lys Phe Arg Arg Ser Leu 305 310 315 320 Leu Gln Leu Leu Cys Leu Arg Leu Leu Arg Cys~Gln Arg Pro Ala Lys 325 330 335

Asp Leu Pro Ala Ala Gly Ser Glu Met Gln Ile Arg Pro Ile Val Met 340 345 350 Ser Gln Lys Asp Gly Asp Arg Pro Lys Lys Lys Val Thr Phe Asn Ser 355 360 365 Ser Ser Ile Ile Phe Ile Ile Thr Ser Asp Glu Ser Leu Ser Val Asp 370 375 380 Asp Ser Asp Lys Thr Asn Gly Ser Lys Val Asp Val Ile Gln Val Arg 385 390 395 400 Pro Leu

Claims (16)

1. CLAIMS 1. An isolated receptor polypeptide having immunomodulatory activity comprising (i) the amino acid sequence of SEQ ID NO: 2 or (ii) a variant thereof which is capable of immunomodulatory activity or (iii) a fragment of (i) or (ii) which is capable of immunomodulatory activity.
2. 2. A polypeptide according to claim 1 wherein the variant (ii) has at least 80% identity to the amino acid sequence of SEQ ID NO: 2.
3. 3. A polynucleotide encoding a polypeptide according to claim 1 or 2.
4. 4. A polynucleotide according to claim 3 which is a cDNA sequence.
5. 5. A polynucleotide encoding a receptor polypeptide which is capable of immunomodulatory activity which polynucleotide comprises: (a) the nucleic acid sequence of SEQ ID NO: I and/or a sequence complementary thereto; (b) a sequence which hybridises under stringent conditions to a sequence as defined in (a); (c) a sequence that is degenerate as a result of the genetic code to a sequence as defined in (a) or (b); or (d) a sequence having at least 60% identity to a sequence as defined in (a), (b) or (c).
6. 6. An expression vector comprising a polynucleotide according to any one of claims 3 to 5.
7. 7. A host cell comprising an expression vector according to claim 6.
8. 8. An antibody specific for a polypeptide according to claim I or 2.
9. 9. A method for the identification of a substance that modulates receptor polypeptides having immunomodulatory activity and/or expression, which method comprises : (i) contacting a test substance and a polypeptide according to claim 1 or 2, a polynucleotide according to any one of claims 3 to 5, an expression vector according to claim 6 or a host cell according to claim 7, and

   (ii) determining the effect of the test substance on the activity and/or expression of the said polypeptide or the polypeptide encoded by said polynucleotide, thereby to determine whether the test substance modulates receptor polypeptide activity and/or expression.
10. 10. A method according to claim 9 wherein the polypeptide is expressed in a cell.
11. 11. A substance which modulates receptor polypeptides having immunomodulatory activity and which is identifiable by a method according to claim 9 or 10.
12. 12. A method of treating a subject having a disorder that is responsive to receptor polypeptide having immunomodulatory activity modulation, which method comprises administering to said subject an effective amount of a substance according to claim 11.
13. 13. A method according to claim 12 wherein the disorder is selected from diseases of immune, autoimmune, immunodeficiency or inflammatory origin such as: asthma, COPD, bronchitis, rhinitis, allergy, rheumatoid arthritis, dermatitis, general inflammation (e. g. tendonitis, bursitis, etc. ), inflammatory pain, Crohn's disease, ulcerative colitis, inflammatory bowel syndrome, gastritis, colitis, Alzhiemer's disease, AIDS, severe combined immunodeficiency, viral infections, bacterial infections, acne vulgaris, septic shock, anaphylaxis, antibody mediated rejection, Type I diabetes mellitus, Goodpasture's syndrome, myasthenia gravis, systemic lupus erythematosis, Grave's disease, and systemic sclerosis, familial cold urticaria and Muckle-Wells syndrome.
14. 14. Use of a substance as defined in claim 11 in the manufacture of a medicament for treatment or prophylaxis of a disorder that is responsive to stimulation or modulation of receptor polypeptide having immunomodulatory activity.
15. 15. A use according to claim 14 wherein the disorder is selected from diseases of immune, autoimmune, immunodeficiency or inflammatory origin such as: asthma, COPD, bronchitis, rhinitis, allergy, rheumatoid arthritis, dermatitis, general inflammation (e. g. tendonitis, bursitis, etc. ), inflammatory pain, Crohn's disease, ulcerative colitis, inflammatory bowel syndrome, gastritis, colitis, Alzhiemer's disease, AIDS, severe combined immunodeficiency, viral infections, bacterial infections, acne vulgaris, septic shock, anaphylaxis, antibody mediated rejection, Type I diabetes mellitus, Goodpasture's syndrome, myasthenia gravis, systemic lupus erythematosis, Grave's disease, and systemic sclerosis, familial cold urticaria and Muckle-Wells syndrome.
16. 16. A method of producing a polypeptide according to claim 1 or 2, which method comprises maintaining a host cell as defined in claim 7 under conditions suitable for obtaining expression of the polypeptide and isolating the said polypeptide.